Souhaitez-vous accéder aux communiqués récents ?

IRVINE, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy® Transcatheter Heart Valve (THV) System, today announced the successful first...

TUCSON, Ariz., April 01, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total...

PHILADELPHIA, April 01, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...

Trevi Therapeutics to host an Investor and Analyst Day on May 7th in NYC and participate in key upcoming events.

GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time...

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Mammography Workstation Market Report 2026" has been added to ResearchAndMarkets.com's offering. The mammography workstation market has witnessed...

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas

Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS portfolio with a...

Company intends to uplist to a national securities exchange in 2026 COSTA MESA, CA, April 01, 2026 (GLOBE NEWSWIRE) -- Charlie’s Holdings, Inc. (OTCQB: CHUC) (“Charlie’s” or the “Company”), an...

PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home...

BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation,...

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Gemcitabine Hydrochloride Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides detailed statistics on global...

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights into...

Austin, April 01, 2026 (GLOBE NEWSWIRE) -- The Microcrystalline Cellulose Market size was estimated at USD 1.30 billion in 2025 and is expected to reach USD 2.61 billion by 2035, growing at a CAGR...

BudPop earns top THCP gummy ranking in 2026 after independent reviewers tested 40+ brands on potency accuracy, lab verification, and ingredient quality.

VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse...

Protein chip market grows to USD 4.79 Billion by 2035 at 6.89% CAGR, driven by proteomics research, and rising clinical diagnostics adoption.

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Outpatient Oncology Infusion Market Report 2026" has been added to ResearchAndMarkets.com's offering. The outpatient oncology infusion market is...

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Oncology Ablation Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive statistics, market size...

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report outlines...

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Avastin (Bevacizumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ...

EINDHOVEN, the Netherlands, April 01, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement,...

uniQure (QURE) Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

ImmunityBio (IBRX) Investors Have Opportunity to Lead ImmunityBio, Inc Securities Fraud Lawsuit

Corcept (CORT) Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate

iGenics eye vitamin supplement ingredients, AREDS-2 dosage context, bilberry extract research, pricing details, and key considerations for 2026.

SpartaMax male enhancement gummies 2026: ingredient profile, per-serving dosage disclosures, gummy format considerations, and product details.

NeuroView AI Glasses 2026: real-time translation, HD capture, AI features, pricing, and key consumer considerations reviewed.

Investors who lost money in CORT after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

2026 Trimology overview: RS2 resistant starch and probiotic formulation details, ingredient research context, pricing, and consumer considerations

Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

Investors who lost money in SLNO after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

NanoDefense Pro 2026: Nano-ingredient label disclosures, colloidal silver context, CELLg8 claims, pricing, and refund terms reviewed for consumers.

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON).   Such investors are...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).   Such...

EMF Shield Home Protection System 2026: company-described whole-home EMF radiation blocking claims, pricing, and product details evaluated.

MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion...

Company enters 2026 with reduced leverage, extended debt maturity and added liquidity Pursues top-line stabilization and margin expansion with strategic brand repositioning to Beyond The Plant...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).  ...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG).  Such investors are advised to...

What the pink salt trick research says about NeuroSalt nerve health claims, ingredients, and supplement facts consumers should verify in 2026.

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:...

Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 ...

TABER, ALBERTA, March 31, 2026 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE-AMERICAN: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction,...

Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND,...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX).   Such investors...